Norinchukin Bank The boosted its position in shares of STERIS plc (NYSE:STE - Free Report) by 12.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 105,868 shares of the medical equipment provider's stock after acquiring an additional 11,624 shares during the quarter. Norinchukin Bank The owned 0.11% of STERIS worth $21,762,000 at the end of the most recent reporting period.
A number of other large investors have also recently added to or reduced their stakes in STE. Dimensional Fund Advisors LP boosted its stake in STERIS by 5.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 909,521 shares of the medical equipment provider's stock valued at $186,961,000 after purchasing an additional 47,637 shares during the period. Forum Financial Management LP boosted its position in shares of STERIS by 7.1% in the fourth quarter. Forum Financial Management LP now owns 1,184 shares of the medical equipment provider's stock valued at $243,000 after acquiring an additional 78 shares during the period. Freedom Investment Management Inc. grew its stake in shares of STERIS by 9.1% in the fourth quarter. Freedom Investment Management Inc. now owns 1,023 shares of the medical equipment provider's stock valued at $210,000 after acquiring an additional 85 shares in the last quarter. Commerce Bank increased its position in STERIS by 22.9% during the fourth quarter. Commerce Bank now owns 6,968 shares of the medical equipment provider's stock worth $1,432,000 after acquiring an additional 1,300 shares during the period. Finally, Allred Capital Management LLC acquired a new stake in STERIS in the 4th quarter worth about $562,000. Institutional investors and hedge funds own 94.69% of the company's stock.
STERIS Trading Up 1.1 %
STE stock traded up $2.41 during midday trading on Thursday, hitting $226.28. The stock had a trading volume of 131,876 shares, compared to its average volume of 524,498. The company has a current ratio of 2.13, a quick ratio of 1.40 and a debt-to-equity ratio of 0.32. The business has a fifty day moving average price of $222.65 and a two-hundred day moving average price of $218.97. STERIS plc has a 1-year low of $200.41 and a 1-year high of $248.24. The firm has a market cap of $22.23 billion, a P/E ratio of 48.05 and a beta of 0.87.
STERIS (NYSE:STE - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share for the quarter, missing the consensus estimate of $2.33 by ($0.01). STERIS had a net margin of 8.66% and a return on equity of 13.91%. On average, sell-side analysts predict that STERIS plc will post 9.08 earnings per share for the current fiscal year.
STERIS Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Friday, March 21st. Investors of record on Thursday, February 20th were issued a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 1.01%. The ex-dividend date was Thursday, February 20th. STERIS's dividend payout ratio is currently 48.41%.
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on STE shares. Stephens restated an "overweight" rating and set a $240.00 target price on shares of STERIS in a research report on Thursday, February 6th. Piper Sandler lifted their price objective on STERIS from $260.00 to $265.00 and gave the company an "overweight" rating in a report on Monday, February 3rd. JMP Securities reissued a "market outperform" rating and set a $265.00 target price on shares of STERIS in a report on Thursday, April 10th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of STERIS in a research report on Monday, April 7th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, STERIS presently has an average rating of "Moderate Buy" and a consensus price target of $258.75.
Check Out Our Latest Research Report on STERIS
STERIS Company Profile
(
Free Report)
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Featured Stories
Before you consider STERIS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.
While STERIS currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
